Insulet (PODD) EBITDA (2010 - 2026)

Insulet's EBITDA history runs 17 years deep, the most recent figure standing at $122.1 million for Q1 2026.

• Quarterly EBITDA rose 37.5% year-over-year to $122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $507.2 million (up 48.87% YoY) and the FY2025 annual result came in at $473.8 million, up 53.38% from the prior year.
• EBITDA was $122.1 million for Q1 2026 at Insulet, down from $146.3 million in the prior quarter.
• Across five years, EBITDA topped out at $146.3 million in Q4 2025 and bottomed at -$26.7 million in Q2 2022.
• A 5-year average of $68.4 million and a median of $56.9 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA sank 201.52% — and 2023, when it jumped 1789.66%.
• Insulet's EBITDA stood at $23.5 million in 2022, then surged by 353.19% to $106.5 million in 2023, then advanced by 2.63% to $109.3 million in 2024, then jumped by 33.85% to $146.3 million in 2025, then declined by 16.54% to $122.1 million in 2026.
• Business Quant data shows PODD's EBITDA at $122.1 million in Q1 2026, $146.3 million in Q4 2025, and $117.7 million in Q3 2025.